Geller Advisors LLC Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Geller Advisors LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,011 shares of the company’s stock after buying an additional 739 shares during the period. Geller Advisors LLC’s holdings in Johnson & Johnson were worth $2,757,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Hamilton Capital LLC raised its holdings in Johnson & Johnson by 6.8% in the 3rd quarter. Hamilton Capital LLC now owns 3,591 shares of the company’s stock worth $574,000 after purchasing an additional 229 shares during the period. SGL Investment Advisors Inc. bought a new stake in Johnson & Johnson during the 3rd quarter valued at approximately $4,638,000. EWA LLC lifted its holdings in Johnson & Johnson by 14.8% in the 3rd quarter. EWA LLC now owns 2,247 shares of the company’s stock worth $341,000 after purchasing an additional 290 shares in the last quarter. Nomura Asset Management Co. Ltd. boosted its stake in Johnson & Johnson by 13.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 1,624,842 shares of the company’s stock worth $263,322,000 after purchasing an additional 192,826 shares during the period. Finally, Y Intercept Hong Kong Ltd raised its position in shares of Johnson & Johnson by 1,960.4% during the third quarter. Y Intercept Hong Kong Ltd now owns 46,875 shares of the company’s stock valued at $7,597,000 after buying an additional 44,600 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Citigroup raised their target price on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Royal Bank of Canada increased their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Morgan Stanley lifted their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $175.67.

Johnson & Johnson Trading Down 0.1 %

Shares of JNJ opened at $149.31 on Monday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company’s fifty day simple moving average is $158.09 and its 200-day simple moving average is $156.40. The company has a market cap of $359.48 billion, a P/E ratio of 21.61, a P/E/G ratio of 2.65 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.66 earnings per share. As a group, analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.32%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.